Abstract Fibrillar aSynuclein is the major constituent of Lewy bodies and Lewy neurites, the protein deposits characteristic for Parkinson's disease (PD). Multiplications of the aSynuclein gene, as well as point mutations cause familial PD. However, the exact role of aSynuclein in neurodegeneration remains uncertain. Recent research in invertebrates has suggested that oligomeric rather than fibrillizing aSynuclein mediates neurotoxicity. To investigate the impact of aSynuclein aggregation on the progression of neurodegeneration, we expressed variants with different fibrillation propensities in the rat substantia nigra (SN) by means of recombinant adeno-associated viral (AAV) vectors. The formation of proteinase K-resistant aSynuclein aggregates was correlated to the loss of nigral dopaminergic (DA) neurons and striatal fibers. Expression of two prefibrillar, structure-based design mutants of aSynuclein (i.e., A56P and A30P/A56P/A76P) resulted in less aggregate formation in nigral DA neurons as compared to human wild-type (WT) or the inherited A30P mutation. However, only the aSynuclein variants capable of forming fibrils (WT/A30P), but not the oligomeric aSynuclein species induced a sustained progressive loss of adult nigral DA neurons. These results demonstrate that divergent modes of aSynuclein neurotoxicity exist in invertebrate and mammalian DA neurons in vivo and suggest that fibrillation of aSynuclein promotes the progressive degeneration of nigral DA neurons as found in PD patients.
Introduction
Parkinson's disease (PD) is the most prevalent neurodegenerative movement disorder, affecting more than 2% of individuals over the age of 60 years. Pathological hallmarks of the disease are the progressive loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc) and the presence of proteinous aggregates termed Lewy bodies within DA neurons, which are predominantly composed of fibrillar aSynuclein [27] . Gene triplication and inherited mutations of aSynuclein cause early-onset PD, demonstrating a crucial role for aSynuclein in the etiology of the disease [11, 17] . However, how aSynuclein induces neurodegeneration remains as elusive as its physiological function.
aSynuclein belongs to the class of intrinsically disordered proteins in solution, but it adopts a partially folded structure upon a variety of environmental stimuli [41] . While membrane bound a-helical aSynuclein does not contribute to aggregation and fibrillation [47] , soluble folding intermediates are thought to be essential for the initiation of aggregation of the protein by a cascade comprising initially soluble, then insoluble oligomers, and finally fibrils as found in Lewy bodies [13] . The predominant physiological species of aSynuclein in cells and brain is a helically folded tetramer with a low propensity to aggregate into fibrils [3] .
Lewy bodies are usually found in living neurons and are also present in 10-15% of healthy, aged individuals [15, 18] . Considering Lewy bodies as a protective sink for misfolded proteins rather than a toxic entity is therefore an attractive, but controversially discussed hypothesis [20] . Given the strong indications that aSynuclein is causally involved in degeneration of nigral DA neurons, it seems likely that oligomeric aSynuclein rather than fibrillar aggregates are the mediators of neuronal death. Consequently, the ''toxic oligomer'' hypothesis was postulated [6, 42, 46] . This hypothesis gained further support by a recent study in several invertebrate and cell-culture model systems of PD which reported increased neurotoxicity upon overexpression of aSynuclein variants that exhibited increased propensity to form oligomeric, prefibrillar structures and decreased propensities to form fibrillar aggregates [22] .
Considering that species like Drosophila and C. elegans do not express aSynuclein orthologs, assessing aggregate formation and correlating aggregates to neurodegeneration to evaluate their relevance for PD should ideally be performed in adult mammalian DA neurons. In addition, PD is a slowly progressing disorder and a correlation of aSynuclein aggregation with the progressive loss of nigral DA neurons has not been assessed so far. To evaluate long-term effects of aSynuclein aggregate formation on DA neuron survival, we expressed aSynuclein variants with different aggregation propensities in neurons of the rat SN and quantified the loss of DA neurons over a time course of 3.5 months. To interfere with aggregation, the single-proline mutation found in the familial A30P mutant was moved to a position within the bsheet rich core of aSynuclein fibrils. The single-proline aSynuclein mutant A56P as well as the triple-proline mutant A30P/A56P/A76P (TP) showed drastically reduced propensity to form proteinase K (PK)-resistant aggregates in vitro and in vivo, confirming the prior characterization of the mutants as prefibrillar aSynuclein variants by biophysical methods and in invertebrates [22] . However, only the aSynuclein species with increased aggregation propensities, human wild-type (WT) and A30P, triggered a further progressing degeneration of nigral DA neurons, and WT aSynuclein showed the highest degree of neurotoxicity after longer term overexpression. Our findings suggest that fibril formation of aSynuclein promotes the progressive degeneration of nigral DA neurons as found in PD patients and show that invertebrate and mammalian DA neurons are differently vulnerable to aSynuclein aggregation.
Materials and methods

AAV-vector production
AAV2 serotype vectors were constructed to express the human WT aSynuclein, the inherited A30P mutation, the two pre-fibrillary aSynuclein mutants A56P and A30P/ A56P/A76P (TP), and EGFP. AAV2 serotype vectors were prepared essentially as previously described [38] . Their genomes consisted of AAV2 ITRs, human synapsin-1 gene promoter driving expression of aSynuclein variants, WPRE for enhanced mRNA stability and bovine growth hormone polyadenylation site. For Western blot assessing expression levels, primary cortical neuronal cultures were prepared from rat embryos at E18. Western blotting and preparation of conditioned medium and cell extracts were performed according to the procedure described previously [26] .
Stereotaxic injection and tissue processing
All surgical procedures, intracerebral stereotaxic vector injections into the left hemisphere SNpc (coordinates were AP: -5.3; ML: ?2.2; DV: -7.7 mm, relative to bregma) and tissue preparations were performed as described [37] . Young adult female Wistar rats (250-280 g) were injected with a total of 2 ll containing 1.2 9 10 8 transducing units. Animals were sacrificed at 2, 4, 8 and 14 weeks after virus injection. 30-lm thick serial coronal sections from both the SN and striatum were collected on a cryostat (Leica) and processed for immunohistochemistry.
Immunohistochemistry
The following primary antibodies against aSynuclein were used: mouse anti-human LB509 and syn211 (1:500, Invitrogen), 5C2 (1:500, Santa Cruz), and mouse anti-aSynuclein (1:500, Clone 42, BD Transduction Laboratories) recognizing human and rat aSynuclein. Immunofluorescent visualization of DA neurons was performed with rabbit polyclonal antibody against tyrosine hydroxylase (TH, 1:1,000, AB152). Monoclonal anti-b-Tubulin was obtained from Sigma. Primary antibodies were applied for 48 h at 4°C followed by 1 h incubation at RT with secondary antibodies on freefloating sections. For indirect immunofluorescence and Western-blot analysis, secondary antibodies against rabbit or mouse IgGs and conjugated with Cy2, Cy3, or horseradish peroxidase were used (Dianova). For the SNpc, every fourth section was used for immunohistochemistry (-4.52 to -6.3 mm, relative to bregma). For the striatum, one rostral and one caudal section were processed for each condition. Bright-field and fluorescent images were taken on an Axioplan microscope equipped with a 16-bit greyscale CCD camera using AxioVision 4.6 software (Zeiss). Some sections were examined with a laser-scanning confocal microscope (Leica TCS SP5) or with an ApoTome (Zeiss).
Quantification of neurodegeneration
For the bright-field microscopy analysis, visualization of DA neurons was performed with rabbit polyclonal antibody against vesicular monoamine transporter 2 (VMAT2, AB1767, Chemicon). Sections were preincubated first with 3% H 2 O 2 /10% methanol for 5 min and then with 5% normal goat serum for 1 h before incubation with the primary antibody VMAT2 (1:3,000, 4°C, 48 h). Incubation with biotinylated secondary anti-rabbit antibody (1:250) at room temperature for 1 h was followed by the avidinbiotin complex (ABC, Vector laboratories) method. The reaction product was visualized using 3,3 0 -diaminobenzidine tetrachloride (DAB, Sigma) as a chromogen.
To estimate the total number of DA neurons, VMAT2-immunoreactive cells were counted by stereology in every fourth brain section in the region of the SNpc (10 sections throughout the SN). VMAT2-positive cells of the ventral tegmental area were excluded from counting. Cell counts were performed in a blind manner using the StereoInvestigator software (MicroBrightField, Bioscience). Unbiased stereological estimates of the total number of VMAT2-positive neurons per SNpc were obtained using the optical fractionator method [43] . Survival of DA neurons was analyzed at 2, 4, 8, and 14 weeks after vector administration, with exception of the EGFP group, which was sacrificed at the last time point only.
PK digest
Insolubility of the human aSynuclein aggregates was demonstrated utilizing a modified version of a PK digestion and immunohistochemistry protocol [12] . Freefloating sections collected from brains 2 and 4 weeks after viral-vector injection were digested in PBS containing 10 lg/ml PK (Invitrogen) for a period of 10 min at 55°C. Longer incubation times with PK resulted in disintegration of the tissue and were therefore avoided. Maximum incubation time and temperature were established in preliminary experiments. Control sections adjacent to the digested ones were incubated in PBS only. Sections were quenched with 3% H 2 O 2 /10% methanol for 8 min and processed for immunohistochemistry using the syn211 antibody, that recognizes human aSynuclein protein.
Immunoreactivity was visualized with the Vector ABC DAB system. All slices were processed simultaneously under strictly the same conditions and image acquisition and measurements were performed with the exact same settings and parameters. Bright-field images of the SN were taken on an Axioplan microscope equipped with a 639 oil immersion objective and using AxioVision software (Zeiss, Germany). Quantitative data were extracted with the MacBiophotonics ImageJ program (NIH, Maryland, USA, http://rsb.info.nih.gov/ij/). To estimate the PK-resistant fraction of aSynuclein, we performed measurements in at least six randomly selected fields per image from at least six images each. Cell somata were excluded from the quantification of the neuropil. As transgene expression was restricted to the injected side in all animals, we used the uninfected contralateral hemisphere as well as EGFP transduced sections to set the lower threshold value to correct for non-specific background. The upper threshold value was defined in undigested control sections.
For Thioflavin-S (ThioS) staining, mounted sections were incubated with 0.05% ThioS (Sigma) in 50% ethanol for 8 min after a quenching procedure to reduce background autofluorescence [39] and antibody incubations. Sections were differentiated in two changes of 80% ethanol for 10 s each, washed three times in large volumes of PBS, incubated with DAPI for 5 min and washed again.
Statistical analysis
Multiple comparisons were made by one-way ANOVA followed by Tukey's honestly significant difference test. The unpaired t test with Welch correction was used for statistical comparison between two groups. Differences were considered significant at p \ 0.05. Statistical tests were performed using the R software package [36] .
Results
Diminished aggregate formation by prefibrillar aSynuclein variants in cultured neurons
The two rationally generated mutants A56P and TP [22] , the inherited A30P mutation, human WT aSynuclein, and EGFP were expressed in cultured primary cortical neurons using AAV2 vectors. The functional titers of the recombinant viral vectors were equal, i.e., all vectors express the same amount of aSynuclein (Fig. 1a) . To validate that the artificial, oligomeric mutants A56P and TP indeed showed strongly impaired aggregation, we assessed the generation of aggregated aSynuclein by probing its resistance against PK digestion. Protein lysates of transduced neurons were digested with PK for either 5 or 30 min and the percentage of PK-resistant aSynuclein was quantified as a measure of aggregate formation. All values were normalized to the respective control levels without digestion. While 18% of WT aSynuclein and 30% of A30P aSynuclein were resistant to PK-digestion, this fraction decreased to\5% for the A56P and TP mutants (Fig. 1b, c) . This observation corroborates results obtained by earlier in vitro studies demonstrating that A56P and TP form less aggregates in solution than WT or A30P [22] .
Diminished aggregate formation by prefibrillar aSynuclein variants in adult DA neurons of the rat SNpc
We then assessed the formation of aggregates in midbrain tissue sections derived from adult rats by quantifying the amount of PK-resistant aSynuclein. These animals were injected into the SNpc with AAV vectors expressing WT, A30P, A56P or TP aSynuclein 4 weeks before tissue sampling. Control rats received identical injections of a AAV vector encoding EGFP. Tissue samples were subjected to the maximum possible dose and incubation time of PK, which was just below the threshold of completely digesting the tissue specimen. Untreated sections adjacent to the treated ones served as controls. This method has been shown to be the most sensitive procedure to detect aSynuclein aggregates in tissue specimen including post-mortem patient's brain [4, 32] . After immunohistochemistry with the human aSynuclein specific antibody syn211, PK-resistant aggregates were identified as small intensely stained inclusions of about 0.5 lm in diameter in cell bodies of DA neurons. The neuropil of untreated slices showed relatively large, focal beadlike swellings immunoreactive for aSynuclein. With PK treatment, we detected smaller profiles but with similar spatial arrangement ( Fig. 2a-o) . PK-resistant aggregates in the neuropil were quantified by calculating the fraction of aSynuclein-positive material using the ImageJ software. PK-resistant aggregates in neuronal cell bodies were quantified by counting of individual aggregates. Without PK treatment, aSynuclein immunoreactivity in the neuropil was equal for all aSynuclein variants 4 weeks post transduction. Following PK treatment, WT and A30P expressing specimen demonstrated significantly higher levels of aSynuclein immunoreactivity as compared to A56P and TP (Fig. 2p) . The number of PK-resistant intraneuronal aSynuclein aggregates was significantly higher in WT-and A30P-expressing neurons (99.1 ± 12 and 53.6 ± 20.6, respectively) compared to A56P-and TP-expressing neurons (5.9 ± 3.3 and 3.4 ± 3.8, respectively) (Fig. 2q) . These PKresistant aggregates did not co-stain with ThioS (Fig. 3) . No aggregates were detectable in neurons of undigested sections, in PK-digested sections after EGFP overexpression or in the contralateral nigra (not shown). In contrast to the biochemical PK-resistance assay conducted with cell lysates from cultured non-DA cortical neurons, we found that expression of WT aSynuclein in adult rat DA neurons produced significantly more aggregates than expression of A30P, suggesting that the duration of the expression, the age of the neurons or the DA environment may differentially impact on aggregate formation.
To study the time course of aggregate formation in our in vivo model, we analyzed tissue sections obtained 2 weeks after viral-vector injection. Abnormally accumulated abundant cytoplasmic PK-resistant aggregates had already developed in nigral neurons overexpressing WT aSynuclein (Fig. 2r ). The detected aggregates had, however, a smaller individual grain size compared with aggregates 4 weeks after injection.
As the aggregates were resistant to PK and thus likely consisted of fibrillar aSynuclein [8, 33] , the extensive prior classification of WT and A30P aSynuclein as fibril-forming variants, and A56P and TP as fibrillization impaired variants [22] was confirmed in DA neurons of adult rats in vivo.
Only fibril-forming aSynuclein variants induce a long-lasting progression of DA neuron degeneration Overexpression of WT, A30P, A56P, TP aSynuclein, and EGFP in rat nigral neurons was performed by means of an AAV2 serotype vector. The efficient transduction of all brains and expression of each construct was confirmed by immunohistochemistry. Neuronal localization of aSynuclein was studied by double immunofluorescence with the dopaminergic-specific marker TH (Fig. 4d-i) . Due to the documented inhibitory effect of aSynuclein on TH expression [45] , all cell counts were performed using immunohistochemistry for VMAT2 (Fig. 4l) .
Survival of DA neurons was first analyzed 2 weeks after vector administration and already showed an extensive loss of DA neurons in the SNpc of animals expressing the human WT aSynuclein (43 ± 3%, compared with the noninjected control side). Only WT aSynuclein caused significant neuronal death at this early time point. Two weeks Fig. 1 Assessment of formation of PK-resistant aggregates in cultured primary neurons. a Western blot analysis of AAV2-expressed aSynuclein using total cell lysates from rat primary cortical neurons 6 days after transduction shows equal expression levels of all aSynuclein variants. Staining with antibody clone 42, which reacts with human and rat aSynuclein. b Western blot for aSynuclein on cell lysates from cortical neurons 6 days after transduction with AAV containing the different aSynuclein variants. The lysates were digested with PK for 0, 5, and 30 min. Staining with human specific antibody syn211. c Quantitative evaluation of band intensities of western blot analysis for 30 min PK digest. Formation of PK-resistant material given in % of undigested aSynuclein variant. Data given as mean ± SD from four independent experiments. Asterisk indicates a significant difference between groups (p \ 0.05, paired t test) Fig. 2 aSynuclein immunoreactivity after PK digestion of SNpc tissue sections at 4 weeks after transduction: formation of PKresistant aSynuclein aggregates in vivo. Staining against human aSynuclein in the SNpc after PK digestion (?PK) or without digestion (-PK). Overview in upper panel (a-e) and higher magnification of the neuropil in middle panel (f-j). Compared to WT aSynuclein (g), PK-resistant aggregates were less abundant in the nigral sections expressing the A30P (h) aSynuclein variant, and nearly absent for A56P (i) and TP (j). Lower panel (k-o) shows highpower images from cell somata of neurons, illustrating a dramatically increased number of small, dense inclusions for WT aSynuclein (l). Those cytoplasmic aggregates were less abundant in the nigral neurons expressing the A30P (m) aSynuclein variant, and nearly absent for A56P (n) and TP (o). Scale bars 15 lm. p Quantification of PK-resistant aSynuclein immunoreactive material in the neuropil of the SNpc 4 weeks after transduction. The difference between undigested (-PK) and digested (?PK) sections was highly significant for all aSynuclein variants except for WT (Welch Two Sample t test). Significant differences between PK-digested groups outlined below the graph (Tukey's, p \ 0.001). q Number of PK-resistant, aSynuclein-immunoreactive aggregates per neuron. Significant differences between PK-digested groups outlined below the graph (Tukey's, p \ 0.001). n = 7 for WT, n = 8 for A56P, n = 14 for A30P, n = 5 for TP. Data are presented as mean ± SD (r) Representative images showing neurons expressing the human WT aSynuclein 2 weeks post injection. PK-resistant aggregates had already developed. They were smaller in size and more numerous compared with aggregates 2 weeks later Acta Neuropathol (2012) 123:671-683 675 later, also the proline mutants of aSynuclein induced significant neurotoxicity. Four weeks after virus injection, we found that about 50% of DA neurons had degenerated in tissue expressing either WT (48 ± 17%), A56P (48 ± 8%) or TP (50 ± 7%) aSynuclein, while 27 ± 9% of DA neurons had died after expression of A30P aSynuclein (Fig. 4m) . Thus, the prefibrillar aSynuclein mutants A56P and TP induced a similar extent of neurodegeneration as compared to WT aSynuclein at this time point. However, in contrast to results obtained in invertebrate and cellular models [22] , prefibrillar aSynuclein did not aggravate DA neuron degeneration compared to WT aSynuclein.
Eight weeks post transduction, WT, A56P, and TP still produced a comparable extent of neurodegeneration (56 ± 19, 54 ± 12, 47 ± 8 and 31 ± 13% of DA neurons had degenerated through expression of WT, A56P, TP and A30P aSynuclein, respectively).
A fourth group of animals was analyzed 14 weeks after vector injections (Fig. 4a-m) . In these brains, 69 ± 11% of DA neurons had degenerated in the WT group, and 39 ± 13% in the A30P group, demonstrating a progressive neuropathology. However, \50% DA neuron loss was detected in the A56P (42 ± 10) and TP (46 ± 8) groups (Fig. 4m) , indicating that expression of these aSynuclein To further characterize PK-resistant aggregates, digested sections were immunofluorescently stained with a aSynuclein antibody, followed by a ThioS stain. We detected abundant ThioS-positive structures in DA neurons independent from aSynuclein expression, i.e., also in DA neurons of the contralateral nigra. However, these structures were in no case immunoreactive for aggregated aSynuclein, although we exploited several different aSynuclein antibodies (Syn211, aa121-135 of human aSynuclein; LB509, aa115-122, generated against Lewy bodies as immunogen; clone 42, aa 91-99 of rat and human aSynuclein; and 5C2, directed against the NAC domain). The figure shows ThioS/aSynuclein (Syn211 antibody, confocal detection) double staining after PK digestion (10 min, 55°C, 10 lg/ml) in SNpc 4 weeks after virus injection. DA neurons in the SN showed several small ThioS-positive inclusions (d-f) and many aSynucleinpositive aggregates (a), however, both structures did not colocalize (g). As shown before, neurons infected with WT aSynuclein (a) showed considerably more aSynuclein aggregates than neurons expressing A56P (b) or TP aSynuclein (c) variants did not cause further progression of DA neuron degeneration. Instead, cell loss through expression of A56P and TP aSynuclein had already reached its maximum and final state at 4 weeks. Toxicity in these models could be entirely attributed to aSynuclein since EGFP controls showed only marginal evidence of degeneration 14 weeks post transduction (5.6 ± 4% cell loss).
To determine whether the reduced number of DA cells in the SN was attributable to an actual loss of cells rather than to a downregulation of the cellular markers used, i.e., the TH enzyme and the VMAT2 protein, we used an antibody to the neuron-specific protein NeuN to label nigral neurons. The NeuN marker revealed a marked loss of SNpc cells on the AAV-aSynuclein-injected side, confirming that the neurons had indeed degenerated. Quantification of NeuN-positive cells in the SNpc of WT aSynuclein-injected animals 4 weeks post transduction revealed a 56% reduction compared to the non-injected side. Percentages of TH-positive cells among NeuN-positive cells were approximately 60% on the unlesioned side and increased on average to 68% on the injected sides, suggesting also a loss of non-DA neurons.
It should be noted that 14 weeks after application of AAV2-WT aSynuclein, we detected only few DA cell bodies which demonstrated immunoreactivity for both, the DA marker TH and human aSynuclein, while robust aSynuclein immunoreactivity persisted in the dystrophic remaining neuritis (Fig. 4j) . In contrast, in TP and A56P expressing brains, many neuronal cell bodies were immunoreactive for TH and aSynuclein, suggesting that DA neurons overexpressing the prefibrillar aSynuclein variants can survive for long periods of time (Fig. 4k ).
Fibrillar and prefibrillar aSynuclein variants are secreted from rat primary cortical neurons aSynuclein is secreted from neurons via exocytosis [26] and aSynuclein-mediated neuropathology could be transmitted from affected to unaffected neurons [10] . To investigate whether progressive degeneration of WT and Fig. 4 Only fibrillar aSynuclein variants induce progressive DA neuron degeneration in vivo. a-i Representative images illustrating nigral DA neurodegeneration and significant overexpression of aSynuclein in the injected hemispheres by double staining for TH (red) and aSynuclein (green). Each column contains rostral-to-caudal coronal sections taken from the same animal and gives an overview of the extent of nigral DA neuron loss induced by expression of WT (d-f) or TP (g-i) aSynuclein at 14 weeks after AAV injection. Nontransduced control sections are shown in a-c. Higher magnification images (j, k) are optical sections of 1 lm and were generated with an ApoTome. DA cell bodies which demonstrated immunoreactivity for both, the DA marker TH and human aSynuclein, were found more frequently for TP than for WT. (l) Representative image of a coronal section showing nigral degeneration in a AAV-WT aSynucleininjected animal. The nigral DA neurons were specifically labeled with an antibody against VMAT2 and with standard DAB immunohistochemistry. The expression of WT aSynuclein led to loss of VMAT2-positive neurons in the SNpc, compared with the contralateral intact side. m Changes in total number of VMAT2-positive cells in SNpc over time, as determined by stereology in the AAV-aSynuclein-WT, A30P, A56P, TP and AAV-EGFP-injected rats (n = 5-6 animals per time point and group). Data are shown as mean ± SD; significant differences between groups outlined below the graph (Tukey's test) b A30P transduced nigral DA neurons is related to enhanced secretion of aSynuclein, we overexpressed the aSynuclein variants in primary cultured neurons and quantified the amount of released aSynuclein in the culture medium. To collect the secreted proteins, the neurons were cultured in fresh medium for 48 h. The supernatant was analysed under denaturing and native conditions (Fig. 5a-e) . Secreted aSynuclein was found to migrate as a single 14 kDa band under denaturing conditions, and at *60 kDa in gels when loaded without DTT/b-ME. aSynuclein WT, and all mutant variants were secreted from neurons. The highest amount was detected in the conditioned medium of WT-transduced cultures (n = 5 experiments), suggesting that enhanced secretion of human WT aSynuclein could contribute to the progressive degeneration induced by this variant.
The amount of released aSynuclein in the conditioned medium correlated with the intracellular expression levels of this protein (Fig. 5f ). In the same set of cultures, endogenously expressed cytosolic protein tubulin was not detected in the culture medium, indicating that aSynuclein release was not the result of membrane leakage caused by cell death. To further corroborate that release of aSynuclein is not caused by dying neurons, we counted aSynucleinpositive neurons in primary cultures at 5, 7 and 9 days post transduction. No substantial decrease in cell number over time was detected. Since we found no sign of increased cell death in neurons overexpressing WT aSynuclein, we can exclude the possibility that the enhanced release of WT aSynuclein into the culture medium is attributable to membrane leakage (Fig. 5g) . The conditioned medium (a) and the whole-cell extracts (b) of transduced cortical neurons were subjected to denaturing gel electrophoresis. Non-denaturing gel electrophoresis of aSynuclein from conditioned medium (c) and of aSynuclein isolated from cell pellet (d) with protein loading control (e). Molecular weight markers in kDa indicated on the right. Release of aSynuclein WT was enhanced compared with the other aSynuclein variants. f Secretion of aSynuclein correlates with its expression levels. Primary cortical neurons were transduced with three different titers of AAV-WT aSynuclein and the levels of intracellular (cell lysate) and released (medium) proteins were analyzed. Secreted proteins were collected for 48 h. In contrast to aSynuclein, tubulin was not released from the cells. g Neurotoxicity of WT and mutants of aSynuclein in rat primary cortical neurons transduced with AAV. Numbers of aSynuclein-positive neurons counted after transduction with respective aSynuclein variants. Expression of WT aSynuclein did not result in a lower number of surviving neurons compared with A30P, A56P and TP aSynuclein after 5 and 7 days, indicating that enhanced release of human WT aSynuclein into the medium was not the result of membrane leakage caused by cell death. Data are shown as mean ± SD Differential striatal axonal pathology induced by aSynuclein fibrillar and prefibrillar variants Nigral aSynuclein overexpression resulted in aSynuclein immunoreactivity in striatal projections of nigral DA neurons. The measured density of DA projections in the striatum correlated with the extent of nigral neurodegeneration, i.e., aSynuclein WT overexpression induced significantly more fiber loss as compared to TP and A30P overexpression (Fig. 6) . aSynuclein immunoreactive striatal fibers displayed large numbers of dystrophic swollen profiles, which colocalized with the DA marker TH and morphologically differed considerably between WT, TP and A30P aSynuclein-expressing specimen (Fig. 7) . Following WT overexpression, extensive beading of neuronal processes could be detected (Fig. 7a, d ). In contrast, TP overexpression resulted in the appearance of large axonal retraction bulb-like structures, while the axon proximal to the retraction bulb showed fewer varicosities (Fig. 7b, e) . A30P overexpression, which in nigral DA neurons resulted in fewer PK-resistant aggregates than WT but more such aggregates than TP, displayed an intermediate axonopathy. It induced fewer small, bead-like varicosities but more large retraction bulb-like profiles than WT aSynuclein (Fig. 7c, f) . Thus, it appeared that aggregating aSynuclein WT resulted in extensive beading of neuronal processes, while less-and non-aggregating aSynuclein variants demonstrated a preference for generating large axonal retraction bulb-like structures. These results suggest that fibrillar and prefibrillar variants of aSynuclein induce different modes of axonopathy in nigral DA neurons.
Discussion
aSynuclein constitutes the major component of Lewy bodies and amyloid plaques [34] , and its causal contribution to the etiology of Parkinson's disease is evident [16] . aSynuclein can adopt several oligomeric and fibrillar Fig. 6 Loss of TH-positive innervation in the striatum after expression of a fibrillar aSynuclein variant (WT) or the prefibrillar variant TP. Representative images illustrating the axonal fiber innervation in the striatum 14 weeks after AAV-mediated gene transfer into the SN. Overview of coronal sections showing transgene expression of EGFP (a), WT aSynuclein (b), and TP aSynuclein (c). Nigrostriatal fiber terminals in the striatum were filled with the transgenic protein.
Immunohistochemical staining for TH (d-f) revealed that in contrast to the AAV-EGFP-injected animals (d), the expression of aSynuclein led to the appearance of degenerative changes and a loss of striatal fibers, which was more pronounced for WT (e). Scale bar 500 lm. g-o Higher magnification images covering the dorsal, medial and ventral area of a representative striatal section of an intact nontransduced control side (g-i), WT-transduced (j-l), and TP-transduced (m-o) brain. TH-immunostained sections showing the extent of loss of striatal innervation. Remaining fibers in the WT aSynucleintreated animals were sparse. Scale bar 100 lm. p Quantification of fiber density revealed a clear reduction in TH-positive striatal innervation in the aSynuclein transduced animals at 14 weeks after injection (significant difference from the EGFP-transduced control group at p \ 0.001). The difference between the WT and TP variant was also significant (p = 0.048), whereas the difference between A30P and TP was not b conformation states, but it is still uncertain which of the different conformational states of aSynuclein mediate neurotoxicity. The present study was motivated by recent results showing that rationally designed mutants of aSynuclein showed dramatically reduced propensity to form insoluble aggregates in solution and in C. elegans, and that these variants of aSynuclein demonstrated enhanced neurotoxicity in mammalian cell lines, Drosophila, C. elegans and cultured rat DA neurons [22] . These results were interpreted as a confirmation of the ''toxic oligomer'' hypothesis in the sense that the primary toxic species of aSynuclein are prefibrillar, putatively soluble oligomeric conformations.
Extensive biophysical analysis demonstrated that the point mutations neither alter the structural properties of the protein as monomer in solution, nor prohibit the formation of an a-helical conformation on the surface of SDS micelles, but strongly differed in their ability to form amyloid fibrils. All variants efficiently bind to phospholipid vesicles. The vesicle affinity of A56P or TP aSynuclein was very similar to that observed for A30P [22] .
We report on a rat model using AAV2 delivery of aSynuclein that differs in the rate of progression and severity in DA pathology based on the variant of AAV2-aSynuclein injected. Human-WT aSynuclein caused a rapid onset of nigral pathology (within 2 weeks), including the abundant presence of PK-resistant aggregates of aSynuclein, and a continuous progressive loss of DA neurons between 2 and 14 weeks. Expression of A30P aSynuclein also caused a gradually progressive loss of DA neurons, but with a later onset compared to WT. The prefibrillar aSynuclein variants produced initially only marginal signs of toxicity (at 2 weeks) followed by a dramatic DA cell death at 4 weeks, however, without further progression. Thus, interestingly, the non-aggregating aSynuclein variants showed clearly different kinetics of toxicity compared to those aSynuclein variants that are able to form fibrils (WT and A30P). Taken together, our results highlight a possible link between fibrillization of aSynuclein and progressive neurodegeneration. We are neither suggesting that the propensity of aSynuclein to aggregate is the only property nor that it is the main property of the protein causing DA neurodegeneration, but our results clearly indicate that aggregation plays a major role in the progression of DA cell loss and that aggregation-impaired mutants have lost the ability to trigger a sustained neurodegeneration.
We demonstrate that the prefibrillar aSynuclein variants A56P and TP form fewer PK-resistant aggregates as compared to WT aSynuclein and the familial A30P mutation, not only in cultured primary cortical rat neurons but also in neurites and cell bodies of adult nigral DA neurons in vivo. Thus, these proteins behaved in vivo as predicted by biophysical assessments in defined solutions [22] . However, in contrast to cell culture and invertebrate models, the prefibrillar mutants did not amplify aSynuclein-related degeneration of rat DA neurons in vivo as compared to the WT protein. Whereas at 4 and 8 weeks after viral-vector application cell death was still comparable between fibrillar WT aSynuclein and prefibrillar aSynuclein-WT, 4,178 objects from n = 5 animals; aSynuclein-TP, 3,837 objects from n = 5 animals; aSynuclein-A30P, 1,856 objects from n = 4 animals variants, WT was the most toxic variant after 14 weeks of expression. Among the mutants, A56P and TP caused a stronger cell loss at 4 and 8 weeks, but they were neither in the beginning (2 weeks) nor at a later stage (14 weeks) more toxic than A30P. Thus, already after 4 weeks, the neurotoxic effect of the prefibrillar mutants appeared to have subsided, because after an initial insult the remaining neurons survived despite the fact that the level of aSynuclein expression remained high. These results show that nigral DA neurons were vulnerable to high levels of either WT or mutant aSynuclein, however, only the fibril-forming WT and A30P variants of aSynuclein caused a progressive form of DA neuron degeneration.
The discrepancy between our current results and previous work conducted in invertebrate models and cultured primary neurons [22] with respect to aSynuclein toxicity highlights the necessity to confirm studies that investigate the neurotoxic consequences of aSynuclein aggregation also in adult mammalian DA neurons in vivo. Given that aSynuclein is a very abundant protein in mammalian brain [19] it is likely that mammalian neurons have developed mechanisms to modulate aSynuclein aggregation, which do not exist in invertebrate neurons. Furthermore, our current results demonstrate that even in rat DA neurons, in vivo expression of oligomeric versus fibril-forming aSynuclein variants can lead to divergent results. In a recent study [44] , it was shown that artificial mutants disrupting salt bridges between bstrands of aSynuclein (E35K or E57K) generated more oligomers and less fibrils than WT or A30P aSynuclein in aggregation assays under certain conditions (but more fibrils under different conditions), and that these mutants were significantly more toxic than WT or A30P aSynuclein for rat DA neurons in vivo. Thus, differences in experimental design with respect to the nature of the aSynuclein mutations (disrupting salt bridges between b-strands through lysine substitutions [44] versus directly disrupting b-sheets through proline substitutions [22] ), viral-vector system and promoter, duration of transgene expression, and readout of aggregate formation in vivo make it difficult to evaluate the toxic oligomer hypothesis, and warrant further studies under more matching conditions. Progressive neurodegeneration and its correlation to the formation of PK-resistant aggregates were assessed in our current study for the first time. The composition of PKresistant aSynuclein aggregates is incompletely defined but ample evidence suggests that they consist at least partially of fibrillar aSynuclein. aSynuclein fibrils generated in vitro [8, 14, 30, 33] , and fibrillar aSynuclein in the detergentinsoluble fraction of human synucleinopathy brains are resistant to PK digestion [30, 33] . In contrast, small-sized oligomers are not PK-resistant as recently shown in brain lysates of A53T transgenic mice [40] . Colocalization of aSynuclein aggregates with the classical amyloid stain ThioS has been reported [2] but it was absent in many other studies [21, 24, 25, 31] . Such colocalization may crucially depend on the accessibility of exposed grooves, which are rich in aromatic residues, on the surface of amyloid fibrils [5] . Despite the missing colocalization with ThioS, the resistance of aggregates of WT or A30P aSynuclein to PK is in agreement with a very stable structure as found in amyloid fibrils.
We report here that fibrillar and prefibrillar aSynuclein variants caused divergent axonal pathologies, further exemplifying that they induce neurotoxicity by different means. Degenerating axons of WT aSynuclein expressing DA neurons displayed a multitude of small varicosities of about 30-50 lm 2 area, but very few large retraction bulblike profiles larger than 300 lm 2 in size. Conversely, axons of TP aSynuclein-expressing DA neurons demonstrated fewer small varicosities but more large retraction bulb-like profiles. Thus, axonal transport and/or structural integrity appear to be differentially affected by the presence of aSynuclein variants which are impaired in fibrillation (A56P/TP) as compared to those variants which have high propensity to form fibrils (WT/A30P).
In our rodent model, the familial A30P mutant was found to be less toxic than human WT aSynuclein at all investigated time points. This is in agreement with another rat model using rAAV2/6-mediated expression of aSynuclein in which WT aSynuclein displayed stronger toxicity than the A30P mutant when assayed 8 weeks post-virus injection [2] . Even though WT and A30P are both fibrillar aSynuclein variants, we provided evidence that A30P is less likely to aggregate in vivo, which is in agreement with many other studies showing that A30P does form fibrils, but fibrillizes more slowly than WT [9, 28] . This could explain, at least in part, the differences in toxicity between these aSynuclein variants, but is most likely not the only reason. The A30P mutation reduces the affinity of aSynuclein for biological membranes and this may have an impact on pathophysiological effects [1] . Indeed, it has been shown that the A30P mutant fails to impair the growth of yeast cells [35] .
Our models demonstrate that aSynuclein overexpression for 4 weeks is sufficient to trigger significant nigral DA cell loss independent of the aSynuclein species. Two weeks after transduction, both the fibrillar as well as prefibrillar proline mutants showed only marginal evidence of degeneration. After 4 and 8 weeks of overexpression, A56P and TP displayed higher toxicity than the A30P mutation. This could be taken as an argument for the toxic oligomer. Nevertheless, at 14 weeks post transduction, the A30P mutant had already reached the same toxic effect as A56P and TP. Those aSynuclein species that have the potential to trigger a gradual progression of neurodegeneration are likely to be the most toxic at long term, even if they do not cause the highest cell loss at intermediate time points. It was reported that A30P induced a time-dependent degeneration process and that at 5 months expression, A30P had caused the same loss of TH-positive nigral neurons as WT aSynuclein [29] . Another study also detected no significant difference in loss of TH-positive neurons between WT and A30P [44] . Likewise, a study in mice did not find any obvious difference in pathogenicity between the WT and A30P mutant form of aSynuclein [25] implying that A30P can induce the same extend of neuronal loss as WT.
We hypothesize that the ability of aSynuclein to form fibrils is required for progressive neurodegeneration. The A53T variant of aSynuclein has an increased aggregation propensity in vitro and forms fibrils more quickly than human WT aSynuclein [28] . The finding that AAV-mediated overexpression of mutant A53T aSynuclein results in progressive, time-dependent DA neuron loss in rats is consistent with our idea. In animals given either WT or A53T aSynuclein, the pathological changes were similar, both quantitatively and qualitatively [23] and the authors noted a similar appearance of aSynuclein-positive cytoplasmic inclusions and granular deposits as described in the present study. In a different report, overexpression of A53T aSynuclein in the rat nigra resulted in protracted, but nevertheless progressive neurodegeneration [7] . The delayed degeneration may be related to the fact that human A53T corresponds to WT aSynuclein in rodents. The demonstrated gradual loss of DA cell bodies in the SN caused by the fibrillar mutant A53T is in agreement with our conclusion, that aSynuclein fibril formation is not an epiphenomenon but mechanistically involved in progressive neurodegeneration.
In conclusion, generation of both soluble oligomers and PK-resistant aggregates of aSynuclein leads to death of mammalian DA neurons in vivo, but formation of PKresistant aggregates is required for the induction of progressive degeneration of DA neurons as found in PD patients. The formation of PK-resistant fibrillar aggregates may thus represent the critical pathomechanism that needs to be targeted to achieve a slowing down of the progression of PD and related synucleinopathies.
